Moxifloxacin improves treatment outcomes in patients with ofloxacin-resistant multidrug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4708-4716

  Chien, Jung Yien ^a,b   Chien, Shun Tien ^b   Chiu, Wei Yih ^a   Yu, Chong Jen ^a   Hsueh, Po Ren ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Chest Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHAMBUTOL; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; STREPTOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CODON; DEATH; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM ANALYSIS; TREATMENT OUTCOME; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTIDRUG RESISTANCE; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; TAIWAN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

AGED; ANTITUBERCULAR AGENTS; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; TAIWAN; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84979505693     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00425-16     Document Type: Article

References (25)

1. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. 2011. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38:516-528. http://dx.doi.org/10.1183/09031936.00073611.
2. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. 2009. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 4:e6914. http://dx.doi.org/10.1371/journal.pone.0006914.
3. Centers for Disease Control and Prevention. 2006. Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 55:1176.
4. Lai CC, Tan CK, Huang YT, Chou CH, Hung CC, Yang PC, Luh KT, Hsueh PR. 2008. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a medical center in Taiwan. Clin Infect Dis 47:e57-e63. http://dx.doi.org/10.1086/591702.
5. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169:421-426. http://dx.doi.org/10.1164/rccm.200310-1380OC.
6. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170:1131-1134. http://dx.doi.org/10.1164/rccm.200407-885OC.
7. Zhao BY, Pine R, Domagala J, Drlica K. 1999. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother 43:661-666.
8. Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY. 2006. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 12:7-11. http://dx.doi.org/10.1089/mdr.2006.12.7.
9. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Bottger EC. 2012. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 67:1088-1093. http://dx.doi.org/10.1093/jac/dks033.
10. Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, Farinotti R, Veziris N. 2010. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 54:4765-4771. http://dx.doi.org/10.1128/AAC.00968-10.
11. WHO. 2014. WHO drug resistance guidelines 2014 companion book. WHO Document Production Services, Geneva, Switzerland.
12. Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed). 2007. Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
13. (R) MYCOTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 31:835-839. http://dx.doi.org/10.1007/s10096-011-1382-z.
14. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard, 2nd ed. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Snider GL, Doctor L, Demas TA, Shaw AR. 1971. Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis 103:625-640.
16. Eurosurveillance Editorial Team. 2013. WHO revised definitions and reporting framework for tuberculosis. Euro Surveill 18:20455. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20455.
17. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 51:6-14. http://dx.doi.org/10.1086/653115.
18. Jo KW, Lee SD, Kim WS, Kim DS, Shim TS. 2014. Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 18:39-43. http://dx.doi.org/10.5588/ijtld.13.0307.
19. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 52:852-857. http://dx.doi.org/10.1128/AAC.01036-07.
20. Kambli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udwadia Z, Rodwell TC, Catanzaro A, Rodrigues C. 2015. Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. Tuberculosis (Edinb) 95:137-141. http://dx.doi.org/10.1016/j.tube.2014.11.003.
21. Bottger EC. 2011. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 17:1128-1134. http://dx.doi.org/10.1111/j.1469-0691.2011.03551.x.
22. Wu H, George K, Willingham V, Cucinotta FA. 2001. Comparison of chromosome aberration frequencies in pre- and post-flight astronaut lymphocytes irradiated in vitro with gamma rays. Phys Med 17(Suppl 1):S229-S231.
23. Pantel A, Petrella S, Veziris N, Brossier F, Bastian S, Jarlier V, Mayer C, Aubry A. 2012. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob Agents Chemother 56:1990-1996. http://dx.doi.org/10.1128/AAC.06272-11.
24. Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR. 2015. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis 19:339-341. http://dx.doi.org/10.5588/ijtld.14.0814.
25. Gillespie SH, Basu S, Dickens AL, O'Sullivan DM, McHugh TD. 2005. Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrob Chemother 56:344-348. http://dx.doi.org/10.1093/jac/dki191.